Alexander Perl, MD: The New FLT3 Inhibitor Gilteritinib is “Well-Tolerated” in AML
1,713 views · Published 12 December 2016 · 9:39 · Indexed 24 October 2026
Channel: American Society of Hematology · 2016 · Nonprofits & Activism
Dr. Perl discusses results from the phase I CHRYSALIS trial, which investigated gilteritinitib in patients with relapsed/refractory acute myeloid leukemia.
More from this channel
-
1:52
Ron Reagan Accepts ASH Award - Stem Cell Research
-
4:25
Sen. Jim Talent's Work on Sickle Cell Disease Legislation
-
3:56
ASH and the Reagans Support Stem Cell Research
-
5:42
The American Society of Hematology Celebrates its 50th Anniversary
-
5:57
David Nathan Receives 2011 Wallace H. Coulter Award for Lifetime Achievement in Hematology
-
5:17
James George Receives 2012 Wallace H. Coulter Award for Lifetime Achievement in Hematology
-
2:21
Congress: Protect NIH funding
-
2:21
Act Now: Tell Congress to Stop Further Cuts to Research Funding